

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 20, 2025

Brilliant Violet 711(TM) anti-human CD27

RRID:AB_2650751

Type: Antibody

Proper Citation

(BioLegend Cat# 356430, RRID:AB_2650751)

Antibody Information

URL: http://antibodyregistry.org/AB_2650751

Proper Citation: (BioLegend Cat# 356430, RRID:AB_2650751)

Target Antigen: CD27

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD27

Description: This monoclonal targets CD27

Target Organism: human

Clone ID: Clone M-T271

Antibody ID: AB_2650751

Vendor: BioLegend

Catalog Number: 356430

Alternative Catalog Numbers: 356429

Record Creation Time: 20231110T034508+0000

Record Last Update: 20240725T074518+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD27.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD27.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yu CI, et al. (2024) Engraftment of adult hematopoietic stem and progenitor cells in a novel model of humanized mice. iScience, 27(3), 109238.

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer cell, 42(5), 759.

Yu CI, et al. (2024) Protocol to construct humanized mice with adult CD34+ hematopoietic stem and progenitor cells. STAR protocols, 5(3), 103155.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer cell, 40(8), 879.

Rhoades NS, et al. (2022) Functional, transcriptional, and microbial shifts associated with healthy pulmonary aging in rhesus macaques. Cell reports, 39(3), 110725.

Rodda LB, et al. (2022) Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell, 185(9), 1588.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.